Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1

Conditions

Obesity 3Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 1Overweight 1Neoplasms 1Metabolic Syndrome 1Inflammation 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Dyslipidemias 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Metformin 21Inositol 13Letrozole 9Exercise 5Surveys and Questionnaires 4Clomiphene 4Tablets 3Estradiol 3semaglutide 2maltodextrin 2drospirenone and ethinyl estradiol combination 2Spironolactone 2Progesterone 2Ethinyl Estradiol 2Diet Therapy 2Contraceptives, Oral, Combined 2Caloric Restriction 2Acupuncture Therapy 2salicylsalicylic acid 1mirabegron 1etonogestrel 1drospirenone 1dapagliflozin 1cetrorelix 1Walking 1Tirzepatide 1Thyroxine 1Thioctic Acid 1Tamoxifen 1Sodium-Glucose Transporter 2 Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Polycystic Ovary Syndrome × semaglutide × 1 year × Clear all
NCT06222437 2026-03-23

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Methodist Health System

Phase 1 Withdrawn

Polycystic Ovary Syndrome

NCT05819853 2025-08-28

RESTORE

University of Colorado, Denver

Phase 3 Recruiting
80 enrolled
Other

Obesity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡